Melanotan Side Effects: What the Research Shows
Nausea and Flushing: Dose-Dependent Observations
melanotan side effects most consistently documented across Phase I trials and observational data are nausea, facial flushing, fatigue, yawning, and stretching. These were the most common adverse events in the 1996 Dorr Phase I study (dose escalation 0.01–0.03 mg/kg/day) and in the Wessells 1998 crossover trial (0.025 mg/kg) [3][5][6].
The nausea and autonomic side effects are mechanistically attributable to central MC4R activation: the Paiva 2017 rat study demonstrated that IV MT-II induced Fos expression in hypothalamic magnocellular neurons and increased oxytocin neuronal firing — the same pathway that mediates yawning, stretching, and nausea-adjacent autonomic responses [26].
Nausea was generally dose-dependent and transient in Phase I. The 2021 qualitative study of 623 forum entries from 205 self-administered MT-II users confirmed nausea and facial flushing as the predominant adverse themes in unmonitored real-world use [23]. In uncontrolled populations, adverse effects may be compounded by unverified compound purity, incorrect doses, and combined sunbed use.
Renal Adverse Events in the Literature
Two published case reports document serious renal adverse events following MT-II use:
Case 1: Renal infarction (Peters et al. 2020). A 45-year-old male who self-administered 27 mg of MT-II subcutaneously over 6 months developed right-sided renal infarction affecting approximately 50% of the kidney. Laboratory findings: CRP 152 mg/L, elevated creatinine (102 µmol/L), hematuria, hypertension (165/95 mmHg). CT confirmed the infarction. Follow-up renal function: 81 mL/min per 1.73 m² (mildly reduced). Proposed mechanism: thrombotic pharmacological effects at cumulative high doses [11].
Case 2: Rhabdomyolysis and AKI (Nelson & Bryant, 2012). A 39-year-old man injected 6 mg MT-II subcutaneously in a single dose (approximately 6× the Phase I starting dose). CPK peaked at 17,773 IU/L at 12 hours, confirming rhabdomyolysis; creatinine 2.25 mg/dL indicated acute kidney injury. ICU admission for 3 days required [12].
Both cases involved doses substantially above the Phase I study range. Neither constitutes evidence from controlled research. They represent the documented renal risk profile from self-administered uncontrolled use.
Mole Changes and Melanocytic Nevi
melanotan and mole changes have been documented in peer-reviewed case reports and regulatory safety notices (HPRA, TGA):
Case 1 (Hueso-Gabriel et al. 2012). A 25-year-old man developed sudden eruption of multiple melanocytic nevi and rapid transformation of existing nevi after Melanotan use. Histopathology revealed dysplastic melanocytic nevi with severe dysplasia [13]. This case was published in the Journal of the American Academy of Dermatology.
Case 2 (Sivyer 2012). A 16-year-old female with FAMMM syndrome who self-injected MT-II and attended UV tanning studios developed general skin tanning, multiple dark melanocytic nevi, and an enlarging nevus in the left groin. Histopathology: dysplastic compound nevus with moderate cytoarchitectural atypia. Three months after cessation, moles lightened and skin color paled [14].
Mechanism: increased MC1R stimulation activates melanocytes in and around nevi — the same pathway driving skin pigmentation — potentially destabilizing existing nevi and stimulating new melanocyte proliferation. The FAMMM case demonstrates heightened risk in individuals with underlying genetic susceptibility, but the Hueso-Gabriel case occurred in a subject without reported baseline genetic risk.
Dermatological monitoring is included in the research protocols referenced in the literature for any study involving sustained MC1R agonist administration.
Research on Adverse Events and Safety Profile
MT-I (afamelanotide/Scenesse) has an established safety record from regulated clinical trials. The 8-year observational study of 115 EPP patients receiving 1,023 implants found only minor adverse events (predominantly nausea); no serious drug-related adverse events were identified [16].
MT-II lacks equivalent regulatory review. Human safety data is limited to small Phase I trials (3–20 subjects) conducted in the 1990s–2000s. The controlled Phase I data documented nausea as the predominant adverse event at 0.025 mg/kg. Serious adverse events in the published record derive entirely from case reports of self-administered, uncontrolled use at doses substantially above the Phase I range.
Regulatory bodies that have issued warnings: US FDA (not approved; sale for human consumption illegal), TGA (Australia — not approved for sale; issued consumer warning), HPRA (Ireland — not authorised; active enforcement actions), MHRA (UK — unlicensed; active warnings).
WADA classifies MT-II under S0 (Non-Approved Substances) as a substance not approved for clinical use by any governmental regulatory authority with performance-enhancing potential; it is prohibited in sport.
Regulatory and Safety Context
MT-I (afamelanotide/Scenesse) is EU/FDA-approved for erythropoietic protoporphyria. It has an established regulatory safety profile under prescription medical supervision.
MT-II has no approved indication in any jurisdiction — not the US (FDA), the EU, Australia (TGA), Ireland (HPRA), or the UK (MHRA). Its human safety record comes from Phase I trials (3–20 subjects per trial) and self-administration case reports in the published literature. The gap between Phase I data and real-world case reports is substantial: the Phase I studies used controlled doses (~0.025 mg/kg) under medical supervision; the serious adverse events in case reports all involve substantially higher cumulative doses under unmonitored conditions.
This site documents what the literature shows. It does not assess whether any particular use of MT-II is safe, legal, or appropriate.
Melanotan II and Hormonal Effects
No controlled trial data on testosterone suppression or elevation by MT-II exists. A rodent study found that MT-II co-infusion with NPY cancelled NPY's orexigenic and adipogenic effects, but did not affect NPY-driven suppression of the gonadotropic axis (LH) or the somatotropic axis (GH) [22]. This indicates that melanocortin signaling at the MC4R pathway level does not modulate gonadal hormone production in that model.
MT-II's pro-erectile signaling operates via central MC4R activation — driving downstream NO-mediated responses in cavernosal tissue — not through gonadal androgen pathways. Testosterone was not a primary or secondary endpoint in any published MT-II human trial. There is no controlled evidence supporting either testosterone-raising or testosterone-suppressing effects.